Pharmaceuticals News and Research

RSS

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

Total economic impact of foodborne illness across the nation to be a combined $152 billion annually

A new study by a former U.S. Food and Drug Administration (FDA) economist estimates the total economic impact of foodborne illness across the nation to be a combined $152 billion annually.

3 Mar 2010

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.

3 Mar 2010

China Nepstar Chain Drugstore reports revenues of US$91 million for fourth-quarter 2009

China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2009.

3 Mar 2010

Astellas commences unsolicited tender offer to acquire common shares of OSI for $52.00 per share

OSI Pharmaceuticals, Inc. today confirmed that Astellas Pharma Inc. has commenced an unsolicited tender offer to acquire all outstanding common shares of OSI for $52.00 per share in cash.

3 Mar 2010

Lotus Pharmaceuticals adds five new prescription drugs to its products

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that it had added five new prescription drugs to its products delivered through its national sales channels.

3 Mar 2010

FDA approves Mylan Pharmaceuticals' ANDA for Ursodiol Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Ursodiol Capsules USP, 300 mg, the generic version of Watson's gastrointestinal agent Actigall® Capsules.

3 Mar 2010

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the signing of a License and Supply Agreement with Kyowa Hakko Kirin that provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Taiwan, Hong Kong, Singapore and Malaysia.

3 Mar 2010

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals, Inc. today announced the sale of its royalty rights from sales of REGPARA® (cinacalcet HCl) to a fund managed by DRI Capital, Inc., (Fund) for $38.4 million. Royalties in excess of cumulative royalties of $96 million or 2.5 times the upfront purchase price have been retained by NPS.

3 Mar 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with Harvard University and the Howard Hughes Medical Institute to provide their researchers with the LEAP™ Cell Processing Workstation.

3 Mar 2010

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Unilife Corporation, today announced that it has agreed to a list of therapeutic drug classes ("Exclusivity List") within which sanofi-aventis has the exclusive right to purchase the Unifill™ ready-to-fill syringe.

3 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

AB SCIEX launches mass-spectrometry-based software application to advance lipid biomarker research

AB SCIEX, a global leader in life science analytical technologies, today announced the launch of the first mass-spectrometry-based software application specifically designed to advance the study of lipidomics.

3 Mar 2010

Impax Laboratories' generic FLOMAX ANDA: FDA grants final approval

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for the generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. The Company also announced that it is commencing shipment through Global Pharmaceuticals, Impax’s generic division.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva’s favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

2 Mar 2010

Abbott and Enanta advance treatment for Hepatitis C

Abbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials.

2 Mar 2010

Activists and lobbyists ramp up efforts in possible final health care push

"In the absence of clear next steps, outside groups have stepped in to beat the drum, keeping time while the leadership meets behind closed doors to write the next movement. ... Progressive advocacy groups like Health Care for America Now and Families USA are organizing supporters and protests across the country, reminding Americans and lawmakers why inaction is unacceptable."

2 Mar 2010

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

MAP Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

Pharmaceuticals News and Research

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Total economic impact of foodborne illness across the nation to be a combined $152 billion annually

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

China Nepstar Chain Drugstore reports revenues of US$91 million for fourth-quarter 2009

Astellas commences unsolicited tender offer to acquire common shares of OSI for $52.00 per share

Lotus Pharmaceuticals adds five new prescription drugs to its products

FDA approves Mylan Pharmaceuticals' ANDA for Ursodiol Capsules

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

AB SCIEX launches mass-spectrometry-based software application to advance lipid biomarker research

Impax Laboratories' generic FLOMAX ANDA: FDA grants final approval

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Abbott and Enanta advance treatment for Hepatitis C

Activists and lobbyists ramp up efforts in possible final health care push

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence